A Novel Subset of Triple-Negative Breast Cancers with Unique Histology and Immunohistochemical Expression

Overview

Journal Iran J Pathol

Date 2022 Apr 25

PMID 35463732

Authors

Swaminathan Kalyanasundaram

Shantaraman Kalyanaraman

Hidhaya Kaleelullah Fathima

Vidhya Mohan

Kavitha Selvaraj

Affiliations

Soon will be listed here.

Abstract

Background & Objective: Triple-Negative Breast Carcinoma (TNBC) is characterized by an absence of estrogen receptor, progesterone receptor and HER2 neu expression, with distinct molecular, histological and clinical features, aggressive clinical course and a poor prognosis. The objective was to evaluate the expression of Cytokeratin5/6 (CK 5/6), Epidermal Growth Factor Receptor 1 (EGFR 1), E-cadherin and Androgen receptor in tissue sections of TNBC.

Methods: All modified radical mastectomy samples received negative for the three markers were subjected to further studies with CK5/6, EGFR 1, E- cadherin and Androgen receptor staining. The clinical and pathological data were tabulated and statistically analysed using the Chi-square test, and cross-tabulation was done to assess the correlation between these markers.

Results: Of 94 samples classified as TNBC, 31 (33%) were positive for CK 5/6, 47 (50%) for EGFR, 32 (34%) for E Cadherin and Androgen receptor, respectively. We had one positive patient for all four markers, 13 patients were negative for all four. Thirty-five cases were positive for only one marker, 32 were positive for two markers, and 13 were positive for three markers. Analysis revealed certain interesting patterns, namely - E cadherin was the most common isolated marker expressed in our cohort of TNBC with 15 of 35 positives.

Conclusion: This study highlights the presence of a unique subtype of TNBC, which are negative for all the four markers studied here, with unique histomorphology of absent tumour necrosis and stromal lymphocytic infiltration being unique.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Bhargava R, Striebel J, Beriwal S, Flickinger J, Onisko A, Ahrendt G . Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol. 2009; 2(5):444-55. PMC: 2655155. View

Kumar V, Srivastava A, Singhal R, Kumar V . Immunoreactive estrogen receptor in breast tumor and adjacent tissue: association with clinicopathological characteristics in Indian population. J Surg Oncol. 2005; 89(4):251-5. DOI: 10.1002/jso.20211. View

Ryu D, Jung M, Choi W, Lee C . Clinical significance of morphologic characteristics in triple negative breast cancer. J Korean Surg Soc. 2011; 80(5):301-6. PMC: 3204700. DOI: 10.4174/jkss.2011.80.5.301. View

Rakha E, Reis-Filho J, Ellis I . Basal-like breast cancer: a critical review. J Clin Oncol. 2008; 26(15):2568-81. DOI: 10.1200/JCO.2007.13.1748. View

Foulkes W, Smith I, Reis-Filho J . Triple-negative breast cancer. N Engl J Med. 2010; 363(20):1938-48. DOI: 10.1056/NEJMra1001389. View

Thiery J . Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002; 2(6):442-54. DOI: 10.1038/nrc822. View

McNamara K, Moore N, Hickey T, Sasano H, Tilley W . Complexities of androgen receptor signalling in breast cancer. Endocr Relat Cancer. 2014; 21(4):T161-81. DOI: 10.1530/ERC-14-0243. View

Shen T, Zhang K, Siegal G, Wei S . Prognostic Value of E-Cadherin and β-Catenin in Triple-Negative Breast Cancer. Am J Clin Pathol. 2016; 146(5):603-610. DOI: 10.1093/ajcp/aqw183. View

10.

Rakha E, El-Sayed M, Green A, Lee A, Robertson J, Ellis I . Prognostic markers in triple-negative breast cancer. Cancer. 2006; 109(1):25-32. DOI: 10.1002/cncr.22381. View

11.

Kashiwagi S, Yashiro M, Takashima T, Nomura S, Noda S, Kawajiri H . Significance of E-cadherin expression in triple-negative breast cancer. Br J Cancer. 2010; 103(2):249-55. PMC: 2906732. DOI: 10.1038/sj.bjc.6605735. View

12.

Plasilova M, Hayse B, Killelea B, Horowitz N, Chagpar A, Lannin D . Features of triple-negative breast cancer: Analysis of 38,813 cases from the national cancer database. Medicine (Baltimore). 2016; 95(35):e4614. PMC: 5008562. DOI: 10.1097/MD.0000000000004614. View

13.

Lerma E, Peiro G, Ramon T, Fernandez S, Martinez D, Pons C . Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). Mod Pathol. 2007; 20(11):1200-7. DOI: 10.1038/modpathol.3800961. View

14.

Choccalingam C, Rao L, Rao S . Clinico-Pathological Characteristics of Triple Negative and Non Triple Negative High Grade Breast Carcinomas with and Without Basal Marker (CK5/6 and EGFR) Expression at a Rural Tertiary Hospital in India. Breast Cancer (Auckl). 2012; 6:21-9. PMC: 3273309. DOI: 10.4137/BCBCR.S8611. View

15.

Hashmi A, Edhi M, Naqvi H, Faridi N, Khurshid A, Khan M . Clinicopathologic features of triple negative breast cancers: an experience from Pakistan. Diagn Pathol. 2014; 9:43. PMC: 3996046. DOI: 10.1186/1746-1596-9-43. View

16.

Kalluri R, Weinberg R . The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119(6):1420-8. PMC: 2689101. DOI: 10.1172/JCI39104. View

17.

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron J, Nobel A . Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100(14):8418-23. PMC: 166244. DOI: 10.1073/pnas.0932692100. View

18.

van Hoeven K, Drudis T, Cranor M, Erlandson R, Rosen P . Low-grade adenosquamous carcinoma of the breast. A clinocopathologic study of 32 cases with ultrastructural analysis. Am J Surg Pathol. 1993; 17(3):248-58. DOI: 10.1097/00000478-199303000-00005. View

19.

Livasy C, Karaca G, Nanda R, Tretiakova M, Olopade O, Moore D . Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2005; 19(2):264-71. DOI: 10.1038/modpathol.3800528. View

20.

Yarden Y, Sliwkowski M . Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2(2):127-37. DOI: 10.1038/35052073. View